EU Trials Register Now Holds Data on Over 50k Studies
Information about more than 50,000 clinical trials is now available on the European Union (EU) Clinical Trials Register.
The register contains data on 31,456 current trials with a EudraCT protocol, of which 5,048 are clinical trials conducted on subjects of less than 18 years of age. It also presents details about 18,700 older pediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
The register, which covers studies that started after May 1, 2004 allows users to search for protocol and results information on both interventional clinical trials that are conducted in the EU and the European Economic Area (EEA), as well as clinical trials conducted outside the EU/EEA that are linked to European pediatric medicine development.
It also maintains a list of patient/consumer organizations who may be able provide information on clinical trials within various disease areas. These are organizations that regularly work with the European Medicines Agency.
For more information about the initiative, click here.
Philip Ward is the European Editor for Applied Clinical Trials.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
